Ukwelashwa kwe-alopecia konga u-80% wezinwele

Abantu abadala abanobunzima i-alopecia i-areatta (AA) eyathatha i-OLUMIANT® (baricitinib) yazuza ukukhula okuphawulekayo kwekhanda, i-elash nezinwele zeshiya futhi cishe u-75% walabo abaphendule i-OLUMIANT 4-mg bathola ukumbozwa kwesikhumba se-90% emavikini angu-52, u-Eli Lilly kanye neNkampani kanye no-Incyte bamemezele namuhla. eMhlanganweni Wonyaka we-American Academy of Dermatology (AAD). NgoFebhuwari 2022, i-US Food and Drug Administration (FDA) yanikeza ukubuyekezwa okubalulekile kwe-OLUMIANT ku-AA eqinile njengomuthi ongaba khona wesifo sokuqala. U-Lilly ulindele izinqumo zokulawula e-US, European Union nase-Japan ngo-2022.

Ekuhlaziyweni okuhlanganisiwe kwamasonto angama-52, iziguli ekuqaleni zazinobunzima obukhulu Ithuluzi le-Alopecia (SALT) amaphuzu angu-85.5 (85.5% ukulahlekelwa izinwele ekhanda, noma u-14.5% ukumbozwa kwezinwele zekhanda); I-AA eqinile ichazwa ngokuba ne-SALT score ≥50 (≥50% ukulahlekelwa izinwele zekhanda). Ekuqaleni, i-69.4% ne-57.9% yayinezinwele eziphawulekayo zamashiya kanye nezinwele ze-eyelash, ngokulandelanayo, njengoba kuchazwe yi-Clinian-Reported Outcome (ClinRO) izikolo ≥2. Isilinganiso seminyaka yobudala yeziguli sasiyiminyaka engama-37.6, kanti ukuqothuka kwezinwele kuqale cishe iminyaka yobudala engama-25 kanye nesilinganiso seminyaka eyi-12.2 kusukela kwaqala izimpawu.

Phakathi kweziguli ezithathe i-OLUMIANT 4-mg, ezimbili kweziyisihlanu (39.0%, n=201/515) zazuza ukukhula okubalulekile kwezinwele ze-scalp, okuchazwa njengesikolo se-SALT ≤20, noma u-80% noma ngaphezulu ukumbozwa kwezinwele ze-scalp, futhi cishe ezintathu ziphumile. kwezine zalezo ziguli (74.1%, n=149/201) nazo zithole amaphuzu e-SALT ≤10, noma u-90% wokumbozwa kwezinwele, emavikini angu-52. Ngokwehlukana, iziguli ezingaphezu kwezimbili kweziyisihlanu ezinezikolo eziyisisekelo ze-ClinRO ≥2 (amashiya: 44.1%, n=154/349; ishiya: 45.3%, n=139/307) zabona ukukhula kabusha okugcwele noma ukukhula kabusha okunezikhala ezincane kumashiya neshiya izinwele.

Phakathi kweziguli ezithathe i-OLUMIANT 2-mg, ezingaphezu kweyodwa kweziyisihlanu (22.6%, n=77/340) zazuza ukukhula kabusha kwezinwele ze-scalp futhi ezimbili kwezintathu zalezo ziguli (67.5%, n = 52/77) zafinyelela ku-90 % noma ngaphezulu ukumbozwa kwezinwele emavikini angama-52. Ngokwehlukana, ngaphezu kweyodwa kweziyisihlanu kanye nesinye kweziguli ezine, ngokulandelana (amashiya: 22.9%, n = 55/240; ishiya: 25.5%, n = 51/200), yabona ukukhula kabusha okugcwele noma ukukhula kabusha okunezikhala ezincane kumashiya kanye neshiya izinwele.

Lokhu kuhlaziya okuhlanganisiwe okuthatha amasonto angu-52 kubonisa ukuqhubeka kwentuthuko esikhunjeni sekhanda, amashiya kanye nokukhula kabusha kwezinwele zenkophe kusukela emiphumeleni yamasonto angu-36 eshicilelwe namuhla ku-New England Journal of Medicine futhi yethulwa ku-2021 European Academy of Dermatology and Venereology (EADV) Congress.

“Kungakhathaliseki ukuthi abantu abane-alopecia areata balahlekelwa yizo zonke izinwele emizimbeni yabo noma amabala anempandla kanye namashiya noma izinkophe ezingekho, lesi sifo esihlasela umzimba wonke singalimaza kakhulu. Lesi sifo sithinta abantu bayo yonke iminyaka, "kusho uBrett King, MD, Ph.D., FAAD, uprofesa ohlangene we-dermatology e-Yale School of Medicine kanye nomlobi ohamba phambili walokhu kuhlaziya. “Ngo-2022, i-OLUMIANT ingaba umuthi wokuqala owake wagunyazwa ukwelapha abantu abadala nge-alopecia areata. Kuyamangaza ukuthi cishe u-40% weziguli eziku-OLUMIANT 4-mg, zonke eziqale okungenani ngo-50% wokulahlekelwa izinwele esikhumbeni, zaba nezinwele ezigcwele noma ezicishe ziphelele zesikhumba sekhanda, futhi ukuthuthukiswa okufanayo kwafinyelelwa phakathi kwalezo ziguli ezinamashiya abalulekile noma izinkophe. ukubandakanyeka.”

Ekuhlolweni kokuphepha kwe-OLUMIANT 4-mg kanye ne-2-mg yesikhathi eside, amazinga ezigameko zezehlakalo ezimbi ezibikwa njalo kuze kube amasonto angama-52 (ukuchayeka emasontweni angama-56 amaphakathi) ayehambisana neviki le-36, isikhathi esilawulwa yi-placebo futhi ahlanganisa ukuphefumula okuphezulu. ukutheleleka ngepheshana, ikhanda elibuhlungu, izinduna, ukutheleleka komgudu womchamo kanye nokwanda kwezimpawu zegazi ezihlobene nemisipha. Bezingekho izimpawu ezintsha zokuphepha.

“Imininingwane yokusebenza kuka-OLUMIANT yesikhathi eside iveza ukukhula kabusha okuphawulekayo kwezinwele zekhanda, ishiya neshiya futhi sijabuliswa ukuthi le miphumela ingasho ukuthini ezigulini. Idatha yethu yokuphepha ye-alopecia areata yengeza obunye ubufakazi kwelinye lamasethi amakhulu futhi amade edatha yokuphepha esigabeni se-JAK inhibitor, okuhlanganisa iminyaka eyisishiyagalolunye neminyaka eyi-19,000 yesiguli kulo lonke uhlelo lwethu,” kusho u-Lotus Mallbris, MD, Ph.D., iphini likamongameli. wokuthuthukiswa kwe-immunology yomhlaba wonke kanye nezindaba zezokwelapha e-Lilly. “Sijabulile ukuthi i-OLUMIANT ingase ibe umuthi ongaba yisifo sokuqala esigunyazwe kulo nyaka kubantu abadala abane-alopecia areata enzima.”